Trial CX-839-008 CANTATA

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

CX-839-008 CANTATA

Full title

A randomized, double-blind, placebo-controlled phase 2 study comparing CB-839 in combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pboi-Cabo) in patients with advanced or metastatic renal cell carcinoma (RCC)

Responsible organization

Urologie MRI Ismaninger Str.22 81675 München Germany

Indications

Classification	Code	Description
-		Other Urological tumors

Trial design

Phase

Status

Recruitment finished

Votes

Initiiation & lock

Date of lock (planned / actual)

Unknown / Unknown

Therapy

Zielgerichtet

Participants

	Function	Prename	Surname	Organization
	Responsible contact			Urologie MRI Ismaninger Str.22 81675 München Germany